3D-printed wound dressings containing a fosmidomycin-derivative prevent Acinetobacter baumannii biofilm formation
- PMID: 37680458
- PMCID: PMC10480667
- DOI: 10.1016/j.isci.2023.107557
3D-printed wound dressings containing a fosmidomycin-derivative prevent Acinetobacter baumannii biofilm formation
Abstract
Acinetobacter baumannii causes a wide range of infections, including wound infections. Multidrug-resistant A. baumannii is a major healthcare concern and the development of novel treatments against these infections is needed. Fosmidomycin is a repurposed antimalarial drug targeting the non-mevalonate pathway, and several derivatives show activity toward A. baumannii. We evaluated the antimicrobial activity of CC366, a fosmidomycin prodrug, against a collection of A. baumannii strains, using various in vitro and in vivo models; emphasis was placed on the evaluation of its anti-biofilm activity. We also developed a 3D-printed wound dressing containing CC366, using melt electrowriting technology. Minimal inhibitory concentrations of CC366 ranged from 1 to 64 μg/mL, and CC366 showed good biofilm inhibitory and moderate biofilm eradicating activity in vitro. CC366 successfully eluted from a 3D-printed dressing, the dressings prevented the formation of A. baumannnii wound biofilms in vitro and reduced A. baumannii infection in an in vivo mouse model.
Keywords: Microbiofilms; Microbiology.
© 2023 The Authors.
Conflict of interest statement
The authors declare no competing interests.
Figures










Similar articles
-
The human antimicrobial peptide LL-37 and its fragments possess both antimicrobial and antibiofilm activities against multidrug-resistant Acinetobacter baumannii.Peptides. 2013 Nov;49:131-7. doi: 10.1016/j.peptides.2013.09.007. Epub 2013 Sep 23. Peptides. 2013. PMID: 24071034
-
Study of genetic diversity, biofilm formation, and detection of Carbapenemase, MBL, ESBL, and tetracycline resistance genes in multidrug-resistant Acinetobacter baumannii isolated from burn wound infections in Iran.Antimicrob Resist Infect Control. 2019 Nov 7;8:172. doi: 10.1186/s13756-019-0612-5. eCollection 2019. Antimicrob Resist Infect Control. 2019. PMID: 31719975 Free PMC article.
-
The Antimicrobial Peptide Octopromycin Suppresses Biofilm Formation and Quorum Sensing in Acinetobacter baumannii.Antibiotics (Basel). 2023 Mar 21;12(3):623. doi: 10.3390/antibiotics12030623. Antibiotics (Basel). 2023. PMID: 36978490 Free PMC article.
-
Insights into acinetobacter war-wound infections, biofilms, and control.Adv Skin Wound Care. 2010 Apr;23(4):169-74. doi: 10.1097/01.ASW.0000363527.08501.a3. Adv Skin Wound Care. 2010. PMID: 20299843 Review.
-
Acinetobacter baumannii Biofilm Formation and Its Role in Disease Pathogenesis: A Review.Infect Drug Resist. 2021 Sep 10;14:3711-3719. doi: 10.2147/IDR.S332051. eCollection 2021. Infect Drug Resist. 2021. PMID: 34531666 Free PMC article. Review.
Cited by
-
Promising New Targets for the Treatment of Infections Caused by Acinetobacter baumannii: A Review.Curr Drug Targets. 2024;25(14):971-986. doi: 10.2174/0113894501319269240819060245. Curr Drug Targets. 2024. PMID: 39225221 Review.
References
-
- Lee C.R., Lee J.H., Park M., Park K.S., Bae I.K., Kim Y.B., Cha C.J., Jeong B.C., Lee S.H. Biology of Acinetobacter baumannii: Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment Options. Front. Cell. Infect. Microbiol. 2017;7:55. doi: 10.3389/fcimb.2017.00055. - DOI - PMC - PubMed
-
- Tacconelli E., Carrara E., Savoldi A., Harbarth S., Mendelson M., Monnet D.L., Pulcini C., Kahlmeter G., Kluytmans J., Carmeli Y., et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect. Dis. 2018;18:318–327. doi: 10.1016/S1473-3099(17)30753-3. - DOI - PubMed
LinkOut - more resources
Full Text Sources